Portal de Periódicos da CAPES

Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

2022; Informa; Volume: 33; Issue: 5 Linguagem: Inglês

10.1080/09546634.2022.2035309

1471-1753

Tiago Torres, Maria João Paiva Lopes, Margarida Gonçalo, Cristina Claro, Maria Júlia Ribeiro de Oliveira, Joana Gomes, Ana Paula Vieira, Patrícia Amoedo, Miguel Alpalhão, Miguel Nogueira, Felicidade Santiago, Martinha Henrique, C. Amaro, Tiago Esteves, Juliana de Jesus Monteiro Alves, Diogo Cerejeira, Pedro Mendes‐Bastos, Mafalda Pestana, Lina Ramos, J. Rocha, Rita Carvalho, Laetitia Teixeira, Manuela Selores, Alberto Mota, Paulo Filipe,

Urticaria and Related Conditions

Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older.This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD.A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported.Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.